Sun Pharma recalls around 55k bottles of generic medication in US
Sun Pharma is recalling approximately 55,000 bottles of a generic medication used to treat bowel disease in the US market. The recall is due to "Failed Dissolution Specifications," according to the US Food & Drug Administration (USFDA). The affected Mesalamine extended-release capsules were manufactured at Sun Pharma's Mohali plant and distributed in the US by Sun Pharmaceutical Industries Inc. Mesalamine capsules are indicated for treating mild to moderate ulcerative colitis. The US generic drug market was valued at around USD 115.2 billion in 2019, with Sun Pharma being a major player in the market. (Source: The Econ...
Source: The Economic Times Healthcare and Biotech News - March 8, 2024 Category: Pharmaceuticals Source Type: news
Alembic Pharma receives final approval from USFDA for generic Mesalamine extended-release capsules
The approved drug is therapeutically equivalent to Salix Pharmaceuticals Inc's reference listed drug (RLD), Apriso extended-release capsules, 0.375 g, it added. The drug has an estimated market size of USD 133 million for the months ended June 2022, Alembic said citing IQVIA data. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 2, 2022 Category: Pharmaceuticals Source Type: news
Sun Pharma gets USFDA nod for generic drug Mesalamine extended release capsules
The company has received approval from the US Food and Drug Administration (USFDA) for the product, a generic version of Pentasa extended release capsules (500 mg), the Mumbai-based drug major said in a statement. As per March 2022 IQVIA Health data, Pentasa had annualised sales of around USD 213 million in the US market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 12, 2022 Category: Pharmaceuticals Source Type: news
Anti-TNF Therapy Tied to Better Outcomes in IBD Patients With COVID-19 Anti-TNF Therapy Tied to Better Outcomes in IBD Patients With COVID-19
In patients with inflammatory bowel disease who contracted COVID-19 infection, anti-TNF therapies were associated with more favorable outcomes than corticosteroids or mesalamine in a systematic review and analysis.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 15, 2021 Category: Gastroenterology Tags: Infectious Diseases News Source Type: news
mesalamine (Lialda)
Title: mesalamine (Lialda)Category: MedicationsCreated: 12/10/2008 12:00:00 AMLast Editorial Review: 11/13/2019 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - November 13, 2019 Category: Nutrition Source Type: news
Diverticulitis
This review notes the mainstay role of oral antibiotics for outpatient management has been challenged; rifaximin and mesalamine have been proposed as possible agents to reduce recurrence but available data do not suggest a substantive benefit. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - October 31, 2018 Category: Consumer Health News Source Type: news
Lymphocytic Colitis Responds Rapidly to Budesonide (CME/CE)
(MedPage Today) -- Corticosteroid outperformed mesalamine and placebo in small randomized trial (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - September 13, 2018 Category: Gastroenterology Source Type: news
Asacol vs. Humira
Title: Asacol vs. HumiraCategory: MedicationsCreated: 10/6/2017 12:00:00 AMLast Editorial Review: 10/6/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - October 6, 2017 Category: Drugs & Pharmacology Source Type: news
mesalamine (Pentasa, Rowasa, SfRowasa, Lialda, Canasa, Apriso, Delzicol)
Title: mesalamine (Pentasa, Rowasa, SfRowasa, Lialda, Canasa, Apriso, Delzicol)Category: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 8/17/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - August 17, 2017 Category: Drugs & Pharmacology Source Type: news
Delzicol (Mesalamine Delayed-Release Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 7, 2017 Category: Drugs & Pharmacology Source Type: news
Asacol HD (Mesalamine Delayed-Release Tablets, Oral) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 3, 2017 Category: Drugs & Pharmacology Source Type: news
Zydus Cadila gets USFDA nod for its ulcerative colitis drug
The company has received final approval from the USFDA for Mesalamine delayed-release tablets in the strength of 800 mg, Zydus Cadila said in a statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 25, 2017 Category: Pharmaceuticals Source Type: news
Zydus Cadila gets USFDA nod for mesalamine tablets
Zydus Cadila was the first to file an Abbreviated New Drug Application (ANDA) for the generic version of Lialda (mesalamine), the company said in a BSE filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 7, 2017 Category: Pharmaceuticals Source Type: news
mesalamine, Lialda
Title: mesalamine, LialdaCategory: MedicationsCreated: 12/10/2008 12:00:00 AMLast Editorial Review: 5/12/2017 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - May 12, 2017 Category: Nutrition Source Type: news
mesalamine, Pentasa, Rowasa, Asacol HD, Lialda, Canasa, Apriso, Delzicol
Title: mesalamine, Pentasa, Rowasa, Asacol HD, Lialda, Canasa, Apriso, DelzicolCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 5/11/2017 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - May 11, 2017 Category: Nutrition Source Type: news
